After Noble Financial and Wedbush gave Axcella Health (NASDAQ: AXLA) a Buy rating last month, the company received another Buy, this time from Leerink Partners. Analyst Thomas Smith maintained a Buy rating on Axcella Health today and set a price target of $9.00. The company’s shares closed last Wednesday at $2.70.
According to TipRanks.com, Smith is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.8% and a 32.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $11.33 average price target, implying a 318.1% upside from current levels. In a report released today, Wedbush also reiterated a Buy rating on the stock with a $10.00 price target.
The company has a one-year high of $5.90 and a one-year low of $1.44. Currently, Axcella Health has an average volume of 90.74K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXLA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
Read More on AXLA:
- Telsey Advisory Remains a Buy on Five Below (FIVE)
- Wells Fargo Keeps Their Hold Rating on Halliburton (HAL)
- UiPath (PATH) Receives a Hold from BMO Capital
- Analysts’ Top Utilities Picks: Brookfield Infrastructure (BIP), PDC Energy (PDCE)
- Analysts Offer Insights on Healthcare Companies: ATAI Life Sciences (ATAI), Agilon Health (AGL) and Aveanna Healthcare Holdings (AVAH)